Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist

• US 9,168,288 B2
• Filed: 04/08/2011
• Issued: 10/27/2015
• Est. Priority Date: 04/09/2010
• Status: Expired due to Fees

• Current Assignee: Sinai Health System
• Original Assignee: Mount Sinai Hospital (Sinai Health System)
• Inventors: Drucker, Daniel J., Baggio, Laurie Lynn
• Primary Examiner(s): Skowronek, Karlheinz R
• Assistant Examiner(s): Coffa, Sergio
• Application Number:
  US13/640,111
• Publication Number:
  US 20130053316A1
• Time in Patent Office: 1,663 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention provides a method of treating a subject having, or at risk of developing, a condition in which functioning of the small or large intestine is impaired, enhancing functioning or preventing damage to the small or large intestine in a subject, or ameliorating inflammation of the small or large intestine in a subject, comprising administering to the subject a GLP-1 receptor agonist. A GLP-1 receptor agonist may also be provided in a pharmaceutically acceptable form in an amount effective to treat or prevent conditions of the small or large intestine. Further, pharmaceutical compositions are provided for the treatment or prevention of conditions of the small or large intestine comprising a GLP-1 receptor agonist, together with a pharmaceutically acceptable carrier, excipient or vehicle.

Claims

1. A method of treating a mammalian subject comprising administering to a subject having a condition in which functioning of the small or large intestine is impaired, a GLP-1 receptor agonist, liraglutide, in an amount that does not significantly lower blood glucose, reduce glucose tolerance, or cause significant body weight loss of the subject, to result in the proliferation of the tissue of the small intestine, large intestine, or both.

2. A method according to claim 1, wherein said agonist is administered in a dose of 5 μ

g/kg per day or less.

3. A method according to claim 1, wherein said agonist is administered in a dose of 0.3 mg per day or less.

4. A method according to claim 1, wherein said agonist is administered in a dose of less than 0.6 mg per day.

5. The method according to claim 1, wherein the amount of GLP-1 receptor agonist administered is effective to increase the size of the intestine in length.

6. The method according to claim 1, wherein the amount of GLP-1 receptor agonist administered is effective to increase the size of the intestine in weight.